HIGHLIGHTS
- who: Med Oncol ( and collaborators from the were treated at Karolinska University Hospital between of Health Sciences, University of Liverpool, Liverpool, UK have published the paper: A retrospective study of SBRT of metastases in patients with primary sarcoma, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate the overall response rate and side effects of SBRT in metastatic sarcoma. The median overall survival time for the patients in this study was 26.3 months; a Kaplan-Meier plot for overall survival is shown in Fig 2a. This study shows that even . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.